Skip to content

Indivior Pharmaceuticals, Inc.

INDV

CIK 0001625297

← back to feed
Revenue (TTM)
$1.2B
+4.3% YoY Q1 Apr 2026
Net Income (TTM)
$196M
+900.0% YoY Q1 Apr 2026
EPS Diluted (TTM)
$1.54
+3,180.0% YoY Q1 Apr 2026
Gross Margin
81.6%
Q1 Apr 2026
Operating Margin
26.5%
Q1 Apr 2026
Net Margin
16.3%
Q1 Apr 2026
Free Cash Flow (TTM)
−$93M
Q1 Apr 2026
Cash
$175M
Q1 Apr 2026
Total Debt
$486M
Q1 Apr 2026
Shares Outstanding
121.92M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings